Evidence map›Paper›PMID 25458053›Full record

ArticleMolecular oncology2015

A novel strategy for targeted killing of tumor cells: Induction of multipolar acentrosomal mitotic spindles with a quinazolinone derivative mdivi-1.

Jingnan Wang, Jianfeng Li, Lucas Santana-Santos, Masahiro Shuda, Robert W Sobol, Bennett Van Houten, Wei Qian

Open access · bronzeAbstract read
In one paragraph

Article in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles.American journal of physiology. Heart and circulatory physiology · 2017
    Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jingnan WangTsinghua University School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China.
Jianfeng LiDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine and Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
Lucas Santana-SantosBiomedical Informatics, and Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Masahiro ShudaMolecular Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
Robert W SobolDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine and Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15213, USA.
Bennett Van HoutenDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine and Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA. Electronic address: vanhoutenb@upmc.edu.
Wei QianDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine and Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA. Electronic address: qianw@upmc.edu.
UPMC Hillman Cancer Center · USUniversity of Pittsburgh · USTsinghua University · CN

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Novel approaches to enhance tumor cell cytotoxicity of alkylating agentsR01CA148629 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2010 to 2021
$3.4M
DNA repair deficient cells for analysisR44GM087798 · NIGMS · TREVIGEN, INC. · PI GEORGE, JAY, SOBOL, ROBERT W · 2010 to 2011
$2.5M
DNA Repair-on-a-Chip: Spatially Encoded Microwell ArraysR44ES021116 · NIEHS · TREVIGEN, INC. · PI ENGELWARD, BEVIN P., GEORGE, JAY · 2013 to 2015
$1.5M
DNA Repair-on-a-Chip: Spatially Encoded Microwell ArraysR43ES021116 · NIEHS · TREVIGEN, INC. · PI ENGELWARD, BEVIN P., GEORGE, JAY · 2011 to 2011
$319k
DNA repair deficient human cells for genomic variation analysisR43GM087798 · NIGMS · TREVIGEN, INC. · PI GEORGE, JAY, SOBOL, ROBERT W · 2009 to 2009
$200k
NCI NIH HHS CA148629NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50CA097190NCI NIH HHS P50 CA121973NCI NIH HHS P50CA121973NCI NIH HHS R01 CA148629NIEHS NIH HHS ES021116NIEHS NIH HHS R43 ES021116NIEHS NIH HHS R44 ES021116NIGMS NIH HHS GM087798NIGMS NIH HHS R43 GM087798NIGMS NIH HHS R44 GM087798
6 · The paper itself

Abstract

Traditional antimitotic drugs for cancer chemotherapy often have undesired toxicities to healthy tissues, limiting their clinical application. Developing novel agents that specifically target tumor cell mitosis is needed to minimize the toxicity and improve the efficacy of this class of anticancer drugs. We discovered that mdivi-1 (mitochondrial division inhibitor-1), which was originally reported as an inhibitor of mitochondrial fission protein Drp1, specifically disrupts M phase cell cycle progression only in human tumor cells, but not in non-transformed fibroblasts or epithelial cells. The antimitotic effect of mdivi-1 is Drp1 independent, as mdivi-1 induces M phase abnormalities in both Drp1 wild-type and Drp1 knockout SV40-immortalized/transformed MEF cells. We also identified that the tumor transformation process required for the antimitotic effect of mdivi-1 is downstream of SV40 large T and small t antigens, but not hTERT-mediated immortalization. Mdivi-1 induces multipolar mitotic spindles in tumor cells regardless of their centrosome numbers. Acentrosomal spindle poles, which do not contain the bona-fide centrosome components γ-tubulin and centrin-2, were found to contribute to the spindle multipolarity induced by mdivi-1. Gene expression profiling revealed that the genes involved in oocyte meiosis and assembly of acentrosomal microtubules are highly expressed in tumor cells. We further identified that tumor cells have enhanced activity in the nucleation and assembly of acentrosomal kinetochore-attaching microtubules. Mdivi-1 inhibited the integration of acentrosomal microtubule-organizing centers into centrosomal asters, resulting in the development of acentrosomal mitotic spindles preferentially in tumor cells. The formation of multipolar acentrosomal spindles leads to gross genome instability and Bax/Bak-dependent apoptosis. Taken together, our studies indicate that inducing multipolar spindles composing of acentrosomal poles in mitosis could achieve tumor-specific antimitotic effect, and mdivi-1 thus represents a novel class of compounds as acentrosomal spindle inducers (ASI).

Indexed as

CentrosomeAnimalsCell DivisionCell Line, TumorDynaminsFemaleGTP PhosphohydrolasesHumansMaleMiceMice, KnockoutMicrotubule-Associated ProteinsMicrotubulesMitochondrial ProteinsNeoplasm ProteinsNeoplasms3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinoneDNM1L protein, humanDynaminsGTP PhosphohydrolasesMicrotubule-Associated ProteinsMitochondrial ProteinsNeoplasm ProteinsQuinazolinonesAcentrosomal mitotic spindleMdivi-1Mitotic catastropheOocyte meiosisSV40 antigens

Identifiers

PMID25458053
PMCPMC4305024
OpenAlexW2092955309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.